Transcriptional CDK Inhibitors as Potential Treatment Option for Testicular Germ Cell Tumors
Type II testicular germ cell tumors (TGCT) are the most frequently diagnosed solid malignancy in young men. Up to 15% of patients with metastatic non-seminomas show cisplatin resistance and a very poor survival rate due to lacking treatment options. Transcriptional cyclin-dependent kinases (CDK) hav...
Main Authors: | Kai Funke, Robert Düster, Prince De-Graft Wilson, Lena Arévalo, Matthias Geyer, Hubert Schorle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/7/1690 |
Similar Items
-
Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors
by: Thomas Robert, et al.
Published: (2020-02-01) -
Cell Cycle-Related lncRNAs as Innovative Targets to Advance Cancer Management
by: Liang XR, et al.
Published: (2023-07-01) -
Functional characterization of the human Cdk10/Cyclin Q complex
by: Robert Düster, et al.
Published: (2022-03-01) -
The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma
by: Johannes Tobias Thiel, et al.
Published: (2022-07-01) -
The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study
by: Elisa Rossini, et al.
Published: (2024-02-01)